

2022-11-28

Endemicity is not a victory: the unmitigated downside risks of widespread SARS-Co...

This work was made openly accessible by BU Faculty. Please [share](#) how this access benefits you. Your story matters.

Version	Published version
Citation (published version):	M. Stoddard, A. Novokhodko, S. Sarkar, D. Van Egeren, L.F. White, N.S. Hochberg, M.S. Rogers, B. Zetter, D. Joseph-McCarthy, A. Chakravarty. "Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission" COVID, Volume 2, Issue 12, pp.1689-1709. https://doi.org/10.3390/covid2120121

<https://hdl.handle.net/2144/47017>

Boston University

Article

Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission

Madison Stoddard ¹, Alexander Novokhodko ², Sharanya Sarkar ³, Debra Van Egeren ⁴,
Laura F. White ⁵, Natasha S. Hochberg ⁶, Michael S. Rogers ^{7,8}, Bruce Zetter ^{7,8}, Diane Joseph-McCarthy ⁹
and Arijit Chakravarty ^{1,*}

¹ Fractal Therapeutics, Lexington, MA 02420, USA

² Department of Mechanical Engineering, University of Washington, Seattle, WA 98195, USA

³ Department of Microbiology and Immunology, Dartmouth College, Hanover, NH 03755, USA

⁴ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304, USA

⁵ School of Public Health, Boston University, Boston, MA 02118, USA

⁶ Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA

⁷ Harvard Medical School, Boston, MA 02115, USA

⁸ Boston Children's Hospital, Boston, MA 02115, USA

⁹ Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA

* Correspondence: arijit@fractaltx.com; Tel.: +1-857-526-1463



Citation: Stoddard, M.; Novokhodko, A.; Sarkar, S.; Van Egeren, D.; White, L.F.; Hochberg, N.S.; Rogers, M.S.; Zetter, B.; Joseph-McCarthy, D.; Chakravarty, A. Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission. *COVID* **2022**, *2*, 1689–1709. <https://doi.org/10.3390/covid2120121>

Academic Editors: Sotirios Tsiodras and Gloria Taliani

Received: 19 August 2022

Accepted: 16 November 2022

Published: 28 November 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The strategy of relying solely on current SARS-CoV-2 vaccines to halt SARS-CoV-2 transmission has proven infeasible. In response, many public-health authorities have advocated for using vaccines to limit mortality while permitting unchecked SARS-CoV-2 spread (“learning to live with the disease”). The feasibility of this strategy critically depends on the infection fatality rate (IFR) of SARS-CoV-2. An expectation exists that the IFR will decrease due to selection against virulence. In this work, we perform a viral fitness estimation to examine the basis for this expectation. Our findings suggest large increases in virulence for SARS-CoV-2 would result in minimal loss of transmissibility, implying that the IFR may vary freely under neutral evolutionary drift. We use an SEIRS model framework to examine the effect of hypothetical changes in the IFR on steady-state death tolls under COVID-19 endemicity. Our modeling suggests that endemic SARS-CoV-2 implies vast transmission resulting in yearly US COVID-19 death tolls numbering in the hundreds of thousands under many plausible scenarios, with even modest increases in the IFR leading to unsustainable mortality burdens. Our findings highlight the importance of enacting a concerted strategy and continued development of biomedical interventions to suppress SARS-CoV-2 transmission and slow its evolution.

Keywords: COVID-19; epidemiology; SEIRS; infection fatality rate; virulence; evolution; mortality

1. Introduction

As the COVID-19 pandemic continues unabated, it is easy to forget that the consensus belief not so long ago (both in the scientific community [1–3] and the popular press [4–7]) was that the deployment of SARS-CoV-2 vaccines would bring the pandemic to an end.

Waning immunity [8,9] and the rapid evolution of viral immune evasion [10,11] have limited the ability of vaccines to block transmission [12,13] and dimmed the prospects for herd immunity to SARS-CoV-2. Of the 16 countries in the world with two-dose vaccination rates above 70% of the population, 12 have experienced their highest level—and the other 4 their second-highest level—of disease transmission during the omicron wave [14,15]. Further underscoring the infeasibility of using the existing vaccines alone to eliminate SARS-CoV-2, settings with extremely high vaccination rates have seen large chains of transmission, even in the presence of other mitigation measures [16] and super-spreader events have been demonstrated in some cases to be driven by vaccine breakthrough cases [17].

With complete eradication of SARS-CoV-2 (the viral pathogen responsible for COVID-19) seemingly off the table, some public-health authorities [18–20] now advocate for a strategy of “learning to live with the virus”. This transition from “pandemic” to “endemic” conditions is thought to be possible as the rate of viral transmission is eventually maintained at a steady-state level by the limited availability of susceptible hosts. In practice, this strategy emphasizes relying on the vaccines’ high level of protection against severe acute disease and hospitalization to limit short-term morbidity and mortality, without taking other steps to limit transmission. A critical assumption underpinning this public-health strategy is that infections with SARS-CoV-2 will lead to milder outcomes over time, either due to the progressive buildup of immunity within individuals or due to viral attenuation.

The progressive buildup of immunity hypothesis posits that upon repeated infections (or vaccinations), individuals develop increased immunity to SARS-CoV-2 infections, which in turn leads to a reduced risk of death upon SARS-CoV-2 infection. This hypothesis relies on the level of immunity increasing within the population. However, the broad population heterogeneity of rates of decline of immunity, coupled with viral immune evasion, may make it challenging for populations to build immunity to SARS-CoV-2 over time. Consistent with this, Bayesian modeling based on Census Bureau data (accounting for waning vaccinal immunity, immune evasion and the pace of vaccinations) suggests that the effective protection against infection in December 2021 (21%, against the omicron variant) was lower than the effective protection against infection in January 2021 (25%, against the ancestral strain) [21].

The viral attenuation hypothesis, on the other hand, posits that natural selection will favor viral variants with reduced virulence, leading to an evolutionary ratchet that monotonically reduces the mortality burden of SARS-CoV-2 infections over time. The strong phrasing of this hypothesis (“emergent viruses evolve to become less virulent over time”) is a commonly held belief [22,23] that is demonstrably false [24]. While in some settings there may be a tradeoff between virulence and transmission such that increased virulence leads to reduced transmission, this is not a general rule. A number of emergent viruses in other species have evolved to be both more transmissible and more virulent over time: examples include feline calicivirus [25], myxomatosis in rabbits [26–28] and H5N2 influenza in birds [29,30]. The historical record also contains multiple examples of human pathogens whose virulence has increased over time. HIV virulence has been shown to have increased steadily since its emergence [31,32], underscored by the recent discovery of a highly virulent strain of HIV that has been circulating for several years [33]. The second wave of the 1918–1919 influenza pandemic was substantially more deadly [34] than the first, with a change in the impacted population such that younger individuals had an elevated risk of death. This increased virulence is attributable to viral evolution, as experiments in *in vitro* and animal systems suggested that the coordinated expression of eight genes unique to the 1918 virus was responsible for the increased lethality [35,36]. For other human pathogens, such as smallpox, virulence fluctuated wildly from one wave to the next [37,38], with the high-virulence (“variola major”) strains showing functional differences from the low virulence (“variola minor”) strains [39,40] in *in vitro* and animal studies. The instability of smallpox virulence over time contradicts the notion of obligatory viral attenuation and may foreshadow similar behavior during the current pandemic. For SARS-CoV-2, the infection fatality rates (IFR) for the alpha, beta, gamma, and delta variants of concern (VOCs) were higher than that of the ancestral strain, while the IFR of omicron appears substantially lower than that of the ancestral strain (see Supplementary Table S3) [41–50].

In addition to changes in the intrinsic virulence of the virus, changes in medical practices or patient characteristics can also lead to substantial shifts in the IFR for SARS-CoV-2. Hospital capacity, treatment protocols, availability and effectiveness of therapies, population age structure [51], pollution exposure [52], seroprevalence [53], and numerous other factors have been shown to impact the IFR (See Supplementary Table S1 for more detail) [41–43,54–61].

Thus, the expectation of a monotonic reduction in SARS-CoV-2 IFR over time deserves closer examination. With this in mind, we sought to explore the effect of increased virulence on the ability of SARS-CoV-2 to transmit efficiently and to use a SEIRS modeling framework to predict the impact of hypothetical changes in IFR on the practicality of “learning to live with the disease”. Using a range of plausible reinfection fatality rates and durations of sterilizing immunity, we explored the effects of an endemic SARS-CoV-2 virus on yearly US COVID-19 mortality.

2. Materials and Methods

2.1. Fitness Disadvantage Incurred by Fatal Patient Outcomes

To calculate the viral fitness disadvantage incurred by COVID-19 fatalities, we estimated the fractional loss of transmissibility that occurs when a patient infected with SARS-CoV-2 dies. We assumed that the distribution of probability of transmission over time is independent of disease severity. We used previously published distributions describing the infectivity of COVID-19 patients over time [62] and the probability of fatal outcome over time during disease progression [63]. We implemented both distributions in Python (version 3.8, Python Software Foundation, Beaverton, OR, USA) to assess loss of transmissibility due to fatal COVID-19 outcomes. Transmissibility over time is represented by a gamma distribution, implemented in the Python SciPy stats module (version 1.9.3, SciPy) with shape 20.52, scale 1/1.59, and loc parameter -12.27 according to He et al. [62]. The likelihood of fatal outcome over time is represented by a log-logistic distribution in the SciPy stats module (version 1.9.3, SciPy) with scale 31.18, shape 6.80, and loc parameter -14.51 according to Bai et al. [63]. To determine the loss of transmissibility that occurs when a patient dies, we converted the probability distribution function (PDF) of time from symptom onset to death to a cumulative distribution function (CDF) representing likelihood of survival over time. Then, we performed the dot product of the transmissibility and survival distributions to determine probability of transmission before death, given that both events occur. The loss of transmissibility due to fatal outcome is 1—the fractional transmissibility before fatal outcome.

$$\text{Loss of transmissibility} \mid \text{fatal outcome} = 1 - p_{\text{survival}}(t) \cdot p_{\text{transmission}}(t)$$

This loss of transmissibility occurs in the fraction of infections resulting in fatal outcome, which is the IFR. Thus, the overall loss of transmissibility is the IFR multiplied by the fractional loss of transmissibility in fatal cases.

2.2. SEIRS Modeling to Predict Endemic Infection and Death Rates

To determine the impact of changes in SARS-CoV-2 properties R_0 , IFR, and duration of natural immunity on yearly US death tolls and infection rates, we varied these parameters in a susceptible-exposed-infectious-recovered-susceptible (SEIRS) epidemiological model under a series of vaccination conditions. SEIRS modeling is a standard epidemiological approach for understanding disease kinetics in a population, and our model structure (SEIRS) was chosen because it is the simplest model structure that captures the necessary complexity: disease incubation, infection, immune waning, and reinfection. We modified the standard SEIRS structure to account for vaccination. The model contains two sets of SEIR compartments representing the differing infection and fatality rates of vaccinated and unvaccinated individuals. We assumed that the vaccine reduces the risk of death given infection (VE_m) and the risk of infection (VE_i) but has no additional impact on transmission in breakthrough cases. Some reports from earlier in the pandemic indicated a 50% reduction in infectiousness associated with vaccine breakthrough cases [64]. However, recent contact-tracing findings, conducted in a household setting with omicron as the prevalent variant, showed no reduction in susceptibility to infection for breakthrough cases for fully vaccinated individuals [50]. Waning vaccinal effectiveness [65] in reducing viral load (which has now been noted for the booster dose as well [66,67] can be further expected to impact the vaccinal reduction in transmission.

We ran the model under two theoretical vaccine acceptance scenarios in the US: a “realistic” scenario in which 70% of the under-65 population is vaccinated while 90% of the over-65 population is vaccinated, and a “perfect compliance” scenario in which 100% of the population is vaccinated. Optimistically, we assumed that the vaccine’s efficacy does not change over time (either due to high immunological durability or repeated boosting).

$$\frac{dS_v}{dt} = -\beta(1 - VEi)S_v(I_v + I_u) + \delta R_v + f\mu - \lambda S_v$$

$$\frac{dE_v}{dt} = -\alpha E_v + \beta(1 - VEi)S_v(I_v + I_u) - \lambda E_v$$

$$\frac{dI_v}{dt} = -\gamma I_v + \alpha E_v - \lambda I_v$$

$$\frac{dR_v}{dt} = \gamma I_v - \delta R_v - \lambda R_v$$

$$\frac{dS_u}{dt} = -\beta S_u(I_v + I_u) + \delta R_u + (1 - f)\mu - \lambda S_u$$

$$\frac{dE_u}{dt} = -\alpha E_u + \beta S_u(I_v + I_u) - \lambda E_u$$

$$\frac{dI_u}{dt} = -\gamma I_u + \alpha E_u - \lambda I_u$$

$$\frac{dR_u}{dt} = \gamma I_u - \delta R_u - \lambda R_u$$

Subscripts *v* and *u* represent the vaccinated and unvaccinated subpopulations, respectively, in each of the SEIR model compartments. *S* represents susceptible individuals without immune protection; *E* represents exposed individuals who are not yet infectious; *I* represents infectious individuals; and *R* represents recovered individuals with natural immunity from infection. The contact rate parameter β is a function of R_0 according to $\beta = \gamma R_0$. In this analysis, we predicted yearly US infections while the duration of natural immunity and the R_0 varied over a range. We also evaluated model-predicted yearly deaths over a range of IFRs and durations of immunity under multiple conditions for R_0 , vaccinal efficacy against infection, and vaccine uptake.

Cumulative deaths and infections are stored in separate variables (Deaths, Infections). Deaths are calculated in an age-stratified fashion to account for a higher degree of vaccination among individuals older than 65 years. Thus, in the model the IFR is calculated for individuals based on whether they are older or younger than 65 years. Consistent with our prior work, we estimated the IFR to be 0.16% in the under-65 population ($\sigma_{>65}$) and 3.34% in the over-65 population ($\sigma_{<65}$) based on age-dependent IFR estimates and the US population age structure [68].

$$\frac{dDeaths}{dt} = \gamma\sigma_{>65}(u_{>65}I_u + v_{>65}I_v[1 - VEm]) + \gamma\sigma_{<65}(u_{<65}I_u + v_{<65}[1 - VEm])$$

$$\frac{dInfections}{dt} = \beta(1 - VEi)S_v(I_v + I_u) + \beta S_u(I_v + I_u)$$

where $v_{>65}$ is the fraction of vaccinated individuals older than 65, $v_{<65}$ is the fraction of vaccinated individuals under 65, $u_{>65}$ is the fraction of unvaccinated individuals over 65, and $u_{<65}$ is the fraction of unvaccinated individuals under 65. These fractions are calculated as follows:

$$v_{>65} = \frac{f_{>65}N_{>65}}{f_{>65}N_{>65} + f_{<65}N_{<65}}$$

$$v_{<65} = \frac{f_{<65}N_{<65}}{f_{>65}N_{>65} + f_{<65}N_{<65}}$$

$$u_{>65} = \frac{(1 - f_{>65})N_{>65}}{(1 - f_{>65})N_{>65} \times (1 - f_{<65})N_{<65}}$$

$$u_{<65} = \frac{(1 - f_{<65})N_{<65}}{(1 - f_{>65})N_{>65} \times (1 - f_{<65})N_{<65}}$$

The values of fixed model parameters are covered in Table 1, while the variable parameters and their ranges are covered in Table 2.

Table 1. Fixed parameters for SEIR model.

Fixed Parameter	Symbol	Value	Source
Latency period	$1/\alpha$	3 days	[69]
Infectious period	$1/\gamma$	10 days	[70]
US population birth rate	μ	0.9% annually	Fixed to death rate
US population death rate	λ	0.9% annually	
US population size	N	330 million	[72]
US population over 65 years	$N_{>65}$	54 million	[73]
US population under 65 years	$N_{<65}$	276 million	[73]

Table 2. Variable parameters for SEIR model.

Variable Parameter	Symbol	Value	Source
Vaccine reduction in risk of infection	V_{ei}	0%, 50%, 90%	[74]
Vaccine reduction in risk of mortality	V_{em}	70%, 90%	[75]
Duration of natural immunity	$1/\delta$	3 to 24 months	[76]
Intrinsic reproductive number	R_0	2 to 9 individuals	[77]
Population IFR for unvaccinated individuals	σ	0.05% to 5%	See Table S3
Fraction vaccinated, over 65 years	$f_{>65}$	90%, 100%	[78]
Fraction vaccinated, under 65 years	$f_{<65}$	70%, 100%	[78]

We used this model to estimate yearly US COVID-19 fatalities under endemic conditions, defined here as occurring when steady-state levels of disease spread are reached and maintained because the level of population immunity is equal to the herd immunity threshold $(R_0 - 1)/R_0$. We assumed that all parameters are fixed within a single simulation (e.g., there are no time-dependent changes in any model parameters), and we ran the simulation for a long interval to ensure steady-state conditions were reached. We also note that in some high IFR scenarios, no steady state would be reached because deaths outpace new births, resulting in population loss. Given that we have demonstrated that COVID-19 mortality has very little impact on transmission, we neglected the impact of COVID-19 fatalities on population size—that is, we did not subtract fatal COVID-19 cases from the infected compartment. We also assumed the birth rate is equal to the death rate, so the population neither grows nor shrinks. This allows for a direct comparison of time-independent annual infection counts and death tolls between different IFR, vaccination, and immunity scenarios. We make the simplifying assumption that newborns are vaccinated or unvaccinated based on the overall fraction vaccinated.

2.3. Code Availability

All simulations and analyses were implemented in Python, and code for running these simulations and plotting the results are available on GitHub in the following repository: <https://github.com/madistod/endemicity> (25 November 2022).

3. Results

3.1. Loss of Viral Fitness Incurred by Patient Death Is Minimal

Figure 1A overlays the transmission probability distribution function (PDF) [62], which describes the distribution of transmissibility over time during one individual’s SARS-CoV-2 infection, and the fatal outcome PDF [63], which describes the likelihood of

death over time since symptom onset in fatal cases. The time to death from COVID-19 is substantially longer than the time to transmission for the virus. The average loss of transmissibility due to a fatal outcome is determined by multiplying a patient's probability of having died over time (the CDF of fatal outcome by time post onset of symptoms) by the transmissibility over time (detailed calculation is provided in the Methods section). Based on these distributions, we determined that the expected loss of infectivity incurred when a patient dies is approximately 1.3% of that patient's overall propensity to transmit (Figure 1B). Thus, the overall loss of transmissibility for a lethal SARS-CoV-2 strain is $1.3\% \times \text{IFR}$, assuming the PDFs for fatal outcome and infectivity over time are unchanged relative to the ancestral strain. Alarmingly, a strain that proved lethal in 100% of patients would thus only suffer a 1.3% loss of transmissibility, as nearly 99% of transmission precedes the average time of death. We note that this 1.3% loss of transmissibility is much smaller than previously observed increases in transmissibility accompanying new variants (Supplementary Table S3), suggesting that a minor loss in transmissibility due to a higher IFR could be readily overcome by improvements in transmissibility [45,79]. Since changes in the IFR do not significantly impact the transmissibility of SARS-CoV-2, there is no evolutionary pressure favoring a reduction in COVID-19 disease severity. This implies that the intrinsic IFR (the IFR in the absence of novel interventions and in an immunologically naïve population) is not likely to steadily decrease over time.




Figure 1. Transmission as a function of time post onset of symptoms (POS) is minimally impacted by fatal COVID-19 outcomes. (A) PDFs for COVID-19 death and transmission over time. (B) Loss of fractional transmissibility over time in fatal cases.

We note that it is possible for novel variants to demonstrate increased virulence in a way that reduces transmissibility, for example, by causing death more rapidly. If variants did emerge that led to rapid death and reduced transmission such variants would be placed at an evolutionary disadvantage and would not spread within the population as efficiently. Thus, variants with higher virulence and reduced transmissibility are possible, but they are not relevant to the analysis here. On the other hand, our analysis suggests that variants with higher virulence and unchanged/increased transmissibility are also possible, as the evolutionary penalty for such variants can be very low. In fact, the recent history of SARS-CoV-2 evolution so far reveals that an increased IFR is not obligatorily associated with a faster timeline to death or reduced transmission. For example, the delta variant (around 80% more transmissible) also had around a 50% higher risk of death (see Supplementary Table S3 for more details). The wide spacing between the time of peak transmissibility and the time of peak mortality risk suggests that the virus may be able to continue to increase transmissibility and virulence at the same time.

3.2. Steady-State Transmission of SARS-CoV-2 Is Extensive

To determine the consequences of permitting widespread SARS-CoV-2 transmission, we simulated the endemic spread of SARS-CoV-2 using a susceptible-exposed-infected-recovered-susceptible (SEIRS) model accounting for the waning of natural immunity against

reinfection (Methods). Endemic disease spread is characterized by a steady rate of reinfections required to maintain the steady-state level of immunity under conditions of immune waning. In Figure 2, we explored the model-predicted steady-state level of US SARS-CoV-2 transmission under six vaccination scenarios: 0%, 50%, or 90% reduction in risk of infection (VEi) with “realistic” or “perfect” vaccine uptake in the population. Our “realistic compliance” scenario assumes 70% of the under-65 population is vaccinated while 90% of the over-65 population is vaccinated. “Perfect compliance” assumes 100% uptake regardless of age.




Figure 2. High yearly US infection counts persist under endemic conditions without vaccines that prevent transmission. Yearly US SARS-CoV-2 infections under the following conditions for vaccine compliance and VEi: Realistic vaccine compliance with (A) 0% VEi, (B) 50% VEi, (C) 90% VEi; perfect vaccine compliance with (D) 0% VEi, (E) 50% VEi, (F) 90% VEi. Green regions represent complete suppression of SARS-CoV-2 transmission.

These simulations demonstrate the challenge inherent in managing a highly transmissible, endemic disease conferring only short-term immunity: extreme levels of infection. Under optimistic assumptions—greater than 70% immunization with a vaccine that reduces risk of infection by 90%, an intrinsic reproductive number (R_0) of 5 and 18-month duration of natural immunity—50 million US infections can be expected annually. An increase in transmissibility to an R_0 of 9 results in nearly 100 million infections, and persistent immune evasion resulting in a 9-month duration of natural immunity (with $R_0 = 5$) would also increase infection counts to approximately 100 million. An accompanying drop in vaccine protection against infection to 50% would result in a staggering infection burden approaching 300 million US infections annually. However, complete suppression of SARS-CoV-2 spread is possible with a vaccine that is highly effective against infection and widely accepted by the population (Figure 2C,F).

3.3. Endemic SARS-CoV-2 Death Tolls Are Highly Sensitive to Changes in IFR and Duration of Immunity

For SARS-CoV-2, the infection fatality rate (IFR) has diverged considerably from the 0.7% of the ancestral strain [44], as IFRs for the VOCs have ranged from 0.21% for omicron to 1.71% for beta (see Supplementary Table S3). As the beta variant was not directly descended from any of the preceding VOCs, and omicron was not directly descended from beta [80], IFRs ranging from 0.2% to 1.6% can be considered as the baseline for SARS-CoV-2. In addition, IFRs of up to 3% have been observed at various points during the pandemic, due to changes in local conditions (See Supplementary Table S1). In this study we have considered IFRs between 0.05% and 5%, with 0.7% considered the baseline, corresponding to the ancestral strain [44]. In Figures 3 and 4, we explored the sensitivity of annual US COVID-19 fatalities to IFR, R_0 , and duration of natural immunity under realistic and perfect vaccine acceptance. We explored multiple R_0 and VE_i conditions but assumed vaccine efficacy against mortality given infection (VE_m) is 90% under all scenarios. In these plots, yellow shading represents regions of parameter space where US COVID-19 deaths are predicted to exceed the approximately 650,000 yearly deaths from heart disease, the current leading cause of death [81]. The green point represents best estimates for the IFR and duration of natural immunity for the ancestral strain. We note that under conditions of an R_0 of 5, realistic vaccination under a VE_i of 50%, and best estimate parameters for IFR and natural immunity (Figure 3E), the model predicts approximately 250,000 US COVID-19 deaths annually.

Our model predicts that COVID-19 can become the leading cause of death in the US under many scenarios, especially if vaccines do not prevent infection or transmission. For example, for a hypothetical SARS-CoV-2 variant with an R_0 of 9, an IFR of 1%, and a 12-month duration of natural immunity, approximately 700,000 US COVID-19 deaths could be expected per year under realistic vaccination conditions if the vaccine does not prevent infection (Figure 3B). We observe that despite a high degree of vaccine efficacy against mortality—90% reduction in risk of death given infection—the region in which US COVID-19 deaths under endemic conditions rival influenza deaths (12,000–52,000 per year, according to the CDC [82]) is small and would require a significant reduction in IFR.

In Figure 4, we performed the same parameter sweep under the assumption that the entire population is vaccinated. Under these conditions, a much more favorable outcome is apparent in some scenarios: complete suppression of SARS-CoV-2, resulting in essentially zero yearly deaths (Figure 4G–I). This is possible when a sufficiently high proportion of the population is vaccinated with a vaccine that prevents most infection. Although the near-suppression scenario (Figure 4D) is favorable, the failed suppression scenarios (Figure 4A–C,E,F) entail significant annual COVID-19 mortality under most conditions despite 100% acceptance of a vaccine that prevents 90% of fatalities in breakthrough cases. As shown in Figure 2, transmission under these scenarios is simply too high for population-level mortality to be controlled by such a vaccine unless the IFR is very low.

Mortality under these high-transmission steady-state scenarios is also impacted by changes in the durability of natural immunity, while changes in R_0 have relatively little impact. This is because R_0 determines the level of immunity required to maintain the steady-state according to a saturating relationship $(1-1/R_0)$, while the durability of natural immunity determines the rate at which immunity must be replenished to attain this steady-state level. The IFR describes the direct proportionality between the number of SARS-CoV-2 infections and COVID-19 fatalities.

In Supplementary Figures S1 and S2, we explore the consequences of SARS-CoV-2 endemicity under a vaccine with a VEM of 70% (compared to 90% in Figures 3 and 4). Based on these plots, we conclude that small losses in vaccine efficacy against mortality can result in substantial increases in population-level mortality. For example, the model prediction for COVID-19 mortality under best-estimate parameters (an R_0 of 5, 18-month duration of natural immunity, and realistic coverage with a vaccine with 50% VEi) is approximately 250,000 if the vaccine prevents 90% of mortality after infection. If this vaccine's VEM is reduced to 70% (Figure S1), the predicted death toll rises to 400,000 per year.




Figure 3. Variation in the duration of natural immunity and IFR can result in catastrophic death tolls. The green point represents parameter values corresponding to best-estimates of immunity and IFR for ancestral SARS-CoV-2. Yearly US COVID-19 deaths under the following transmissibility (R_0) and VEi conditions: (A–C) 0% VEi and R_0 of 2, 5, and 9; (D–F) 50% VEi and R_0 of 2, 5, and 9. (G–I) 90% VEi and R_0 of 2, 5, and 9. Vaccine compliance is 70% among under-65 year olds and 90% among over-65 year olds, and VEM is 90% in all panels.




Figure 4. SARS-CoV-2 containment through highly effective vaccination mitigates mortality risks related to variability in IFR and immunity. Green point represents parameter values corresponding to best-estimates of immunity and IFR for ancestral SARS-CoV-2. Yearly US COVID-19 deaths under the following transmissibility (R_0) and VEi conditions: (A–C) 0% VEi and R_0 of 2, 5, and 9; (D–F) 50% VEi and R_0 of 2, 5, and 9. (G–I) 90% VEi and R_0 of 2, 5, and 9. Vaccine compliance is 100% and VEM is 90% in all panels.

3.4. Relationship between R_0 and Yearly Death Toll Is Saturating

Figure 5 elucidates the relationship between R_0 and yearly US COVID-19 mortality. As R_0 increases, the yearly endemic death toll increases, but this relationship saturates as R_0 increases. This means that in scenarios where SARS-CoV-2 is contained by a slim margin, significant outbreaks may be possible with small increases in R_0 or losses of VEi. Additionally, changes in contact behavior or vaccine efficacy against infection are most impactful when the R_0 is closer to 1, while measures that minimally reduce transmission under a high R_0 may have little impact on overall mortality. Under endemic conditions, immune evasion resulting in changes in vaccine efficacy, or the durability of natural immunity, are likely to be more impactful than further increases in transmissibility.




Figure 5. Relationship between R_0 and yearly US deaths is nonlinear. Assuming the duration of natural immunity is 18 months, the population IFR is 0.68%, and VE_m is 90%, endemic US COVID-19 death tolls were simulated under a variety of vaccination scenarios.

3.5. Emergence of New Variants May Rapidly Drive Infection Levels Exceeding the Steady State

The emergence of new SARS-CoV-2 variants with increased transmissibility and/or immune evasion may result in significant infections above the steady-state level in short periods of time, as observed during the omicron wave. For example, the recent omicron wave (12 August 2021–24 February 2022) led to 30 million recorded COVID-19 cases [83], which corresponds to 75 million infections using an infection:case ratio of 2.5 [84]. (This is the low end of the range of published estimates [85–87] and likely to be an undercount due to the high positivity rate [88] and reduced sensitivity to detection [89] seen during the omicron wave.) Table 3 illustrates the challenges with managing death tolls from waves of this size: preceded shifts in IFR (such as those described in Supplementary Table S1) can result in mass casualties in short periods of time.

Table 3. Large waves of infection can lead to catastrophic death tolls with IFRs that are consistent with previous variants. These numbers assume no vaccine.

Infections	IFR 0.5%	IFR 1%	IFR 2%
50 million	250,000	500,000	1,000,000
100 million	500,000	1,000,000	2,000,000
200 million	1,000,000	2,000,000	4,000,000

4. Discussion

The work in this paper demonstrates the risks of COVID-19 management strategies that focus on limiting disease severity while permitting unmitigated spread. The high level of endemic disease propagation will prove challenging for healthcare systems to manage effectively, jeopardizing the ability of healthcare professionals to detect disease when it is most tractable to antivirals, identify patients at risk of severe outcomes, and optimally distribute treatment. This vast infection burden may translate into hundreds of thousands of COVID-19 fatalities even if vaccines reduce the risk of COVID-19 mortality by 90%. Importantly, although this paper focuses on mortality, these infections are expected to cause extensive long-COVID morbidity as well [90]. These steady-state, endemic disease conditions may also be interrupted by waves of transmission driven by immune-evading variants such as omicron. Most concerning, SARS-CoV-2 may not be subject to evolution-

ary pressure favoring lower virulence, and slight changes in the IFR of novel variants may lead to unanticipated—and potentially catastrophic—public-health outcomes on both a chronic and an acute basis.

Overly optimistic predictions about the end of the ongoing pandemic [1–7] have tremendously complicated the public-health response to the crisis. Two aspects of viral behavior in particular were underestimated for SARS-CoV-2: its evolutionary potential and the challenges inherent in a vaccine-only strategy (due to waning vaccinal immunity and low population-level compliance). These risks were in fact predictable. The impact of waning vaccinal immunity was identified as a threat to the feasibility of achieving vaccine-mediated herd immunity well before it came to pass [68]. The rapid emergence of immune evasion in response to widespread population immunity was predicted by us and others [10,91], as was the infeasibility of relying on vaccines alone to permit a return to pre-pandemic conditions [68,92,93]. Going forward, risk mitigation for this pandemic is threatened by an insufficient examination of the full downside potential of the situation at hand. In particular, the prediction of sustained low IFRs for future SARS-CoV-2 variants is an optimistic one. We show in this paper that it lacks a rigorous theoretic justification, and the consequences of this miscalculation could be immense.

The public (and public-health authorities) have taken “learning to live with this disease” as an inevitable consequence of the ineffectiveness of measures to reduce widespread transmission. This frames a false dichotomy [94] between eliminating SARS-CoV-2 and permitting its rampant spread. While it is relatively unrealistic to eliminate SARS-CoV-2 in the short term, reducing transmission is a necessary first step in managing the public-health burden of this disease. Many other pathogens that are considered to be extremely difficult to eliminate (such as influenza, tuberculosis, and malaria) have been the subject of long-term, globally coordinated efforts at disease suppression. Accepting that tuberculosis is difficult to eliminate, for example, is not synonymous with permitting its unrestrained spread across the globe.

Using the United States as an example, we note that the COVID-19 fatalities associated with the ancestral variant’s IFR (0.68%), vaccine parameters, and estimated duration of sterilizing immunity for COVID-19 (18 months) can be estimated at around 250,000 per year. The death toll due to COVID-19 vastly exceeds the mortality burden of the other leading infectious diseases in the US [95]. Accepting a new leading cause of death in the United States for the indefinite future will have profound impacts on life expectancy (as estimated by others based on 2020 data [96,97]), and public-health planning should treat these impacts as the best-case scenario, instead of optimistically planning for them to reduce over time.

In fact, our work suggests that “learning to live with the disease” leads to a fragile outcome where the morbidity and mortality burden of the pandemic can be dramatically impacted by small shifts in IFR. The global experience with the omicron variant demonstrates that new waves of disease driven by emergent SARS-CoV-2 variants can spread extremely quickly, building to high levels of disease before the IFR can be reliably estimated. In the case of omicron, preliminary estimates suggest that the IFR is considerably lower than that of the ancestral strain; the current work suggests that such an outcome is not guaranteed in the future. In a future scenario where an omicron-like variant sweeps quickly through the global population, but this time with a catastrophically high IFR, the unanticipated, lagging wave of death will be difficult to avoid after the fact of widespread infection. Our work also shows that the IFR need not be that high to cause catastrophe: an IFR of 1% is within the range of observed SARS-CoV-2 IFRs (see Supplementary Table S3) and would result in vast, rapid loss of life under an omicron-like variant wave. (For reference, the “mild” omicron wave caused 150,000 US deaths in the span of two months [78]) A significant public-health risk at this point is the emergence and rapid spread of a new variant with an unexpectedly high IFR that only becomes apparent after it is too late to mitigate transmission.

Several authors have taken the position that while increases in viral virulence may be possible, they are not likely. Using the analogy of wearing seatbelts when in a car, a worst-case scenario does not have to be likely for the risk to be worth mitigating. Increases

in the IFR can occur due to direct virological factors (changes in viral load or immune evasion) or due to indirect factors (such as changes in viral tropism or pathology that erode the effectiveness of ICU interventions currently suppressing the IFR). Small, precedented changes in IFR (such as the changes described in Supplementary Table S1, for example) could lead to significant increases in COVID-19 death tolls in the US.

From the standpoint of evolution, there are at least two mechanisms by which a virus can simultaneously access higher lethality and improved transmission: increased viral load and innate immune evasion. Increased viral loads have been demonstrated to improve transmissibility as well as increase virulence for other diseases [25–30,33]. The alpha and delta variants of SARS-CoV-2 were associated with increased viral load [98–100] as well as increased virulence [41,42] (relative to the ancestral strain). Innate immune suppression has been associated (in the case of other viruses) with improved reinfection potential, as well as dramatic increases in mortality (for example with the rabbit disease myxomatosis [101]). SARS-CoV-2 is proficient at suppressing the innate immune response [102–104], targeting key innate immune effectors such as Type I interferon signaling [105,106] to delay the emergence of symptoms until after transmission has peaked. Many SARS-CoV-2 viral proteins have been implicated in innate immune suppression, such as ORF9b [107,108], ORF9c [109,110], Nsp1 [111,112], N protein [113,114], ORF3b [114], ORF6 [113,114], and ORF8 [113]. This trait is not mediated by the spike protein (which dominates the antibody-mediated immune response [115,116], and thus can be expected to evolve independently of immunogenicity. Notably, enhanced innate immune evasion has already been observed for SARS-CoV-2, as recent variants of SARS-CoV-2 (alpha, delta, and omicron) all demonstrate robust overexpression of the N protein, as well as the protein products of the Orf 9b and Orf 6 genes [117]. The unique aspects of SARS-CoV-2 transmission thus provide a biological basis by which increased virulence may provide a fitness advantage to future variants of SARS-CoV-2.

Our work has several key limitations. The model does not account for evolution-mediated vaccine resistance or waning of vaccinal immunity and thus assumes vaccines retain their high efficacy over the simulation interval. This is likely to be an optimistic assumption that has the impact of mitigating model-predicted death tolls. Our work does not explicitly model vaccines or boosters; a full exploration of the impact of vaccines on viral evolution is outside the scope of this work but explored by us elsewhere (manuscript in preparation). Similarly, the interplay between the kinetics of antibody decay and population heterogeneity in the rate of waning of natural and vaccinal immunity will impact the level of protection that vaccines provide, and a full treatment of these effects is outside the scope of this work but described in a different work by us [118]. Moreover, our work did not examine the impact of hospitalization on transmission. It is possible that a patient's propensity to transmit may be reduced upon hospitalization. However, studies so far suggest that the average time to hospitalization from symptom onset is 10–12 days [119], while only 0.3% of transmissibility remains on day 10. Additionally, evidence for reduced SARS-CoV-2 transmission in the hospital setting is also limited: a recent NHS study suggested that 35% of COVID patients contracted COVID while in the hospital [120], suggesting a lack of effective infection controls in the hospital setting. As is true of all SEIR-type models, ours assumes homogenous population mixing and thereby overestimates the kinetics of viral spread and can underestimate the benefits of reduction in transmission at low viral prevalence. However, given the long time-frame of our model, these kinetics are not expected to substantially impact our conclusions. Although the model predicts long-term outcomes under endemic conditions, it is not designed to account for the impact of changes in population size over time due to excess COVID-19 mortality. We explore IFRs up to 5%, but the true span of possible IFRs may be larger (for example, case fatality rate estimates for coronaviruses SARS and MERS-CoV span ranges between 10–50% [121,122] and 20–40% [123–125], respectively). Lastly, our model assumes that natural immunity does not provide protection from mortality beyond protection from infection. The impact of a durable shift in IFR for reinfections can be estimated by selecting a lower IFR estimate

in the analyses provided to reflect endemic conditions (under which virtually all infections will be reinfections, apart from those in young children, who experience a low IFR in general). The work presented here should be viewed not as a specific prediction about the future, but rather as an exploration of the strategic implications of permitting widespread viral transmission while relying on vaccines to limit short-term morbidity and mortality.

In this context, given the poor performance of the first generation of SARS-CoV-2 vaccines in limiting variant spread, our work points to the critical importance of additional means of mitigating transmission. Designing biomedical interventions (antiviral prophylactics, mucosal vaccines) that can reduce transmission while resisting viral immune evasion remain a crucial unmet need in the current crisis. Antiviral prophylactics can provide vital assistance to vaccines by providing an orthogonal selection pressure (on non-spike proteins) that retards the emergence of novel immune-evasive variants. Multiple groups have reported the robust induction of mucosal immunity with nasal SARS-CoV-2 vaccines [126–134], and designing such vaccines to be robust to viral evolution would provide a powerful tool for limiting transmission. Nonpharmaceutical interventions (NPIs) also play a crucial supporting role in managing the downside risk of the pandemic; a number of NPIs including masking [135], air filtration [136], and contact restrictions [137] have demonstrated effectiveness in reducing transmission. In the current context, the widespread loss of NPIs raises the risk of the emergence of variants such as those described in this paper. Widespread and systematic surveillance of viral transmission is key to enable the rapid implementation of nonpharmaceutical interventions to limit the risk of sudden shifts in virulence.

As we grapple with the reality of a long-running pandemic, there is a strong temptation to cast current events in an optimistic light. The actual trajectory of the pandemic so far has been bleak beyond all projections—two years in, we now have over one million dead in the US alone, with rapidly waning vaccinal and natural immunity facing off against a virus that is much more contagious than the ancestral strain. Against this backdrop, the fact that the existing vaccines still work to prevent severe disease and death provides us a bulwark against catastrophe. The work presented here demonstrates the consequences if this last line of defense is breached by viral evolution. In doing so, it underscores a key reality for risk mitigation during this pandemic: that unthinkable and impossible are not the same thing. A greater focus needs to be placed on biomedical interventions and public-health strategies that are robust to viral evolution.

5. Conclusions

In this work, we have demonstrated that the delay in COVID-19 death relative to SARS-CoV-2 infection means that the disease's IFR has minimal impact on its ability to transmit. This suggests that the IFR may be free to increase or decrease under neutral evolutionary drift. Using an SEIRS model, we evaluated steady-state, endemic SARS-CoV-2 dynamics under a variety of vaccination, viral reproductive number, and immunity duration conditions. These simulations predict a high burden of SARS-CoV-2 infections—exceeding 100 million in the US yearly under many plausible scenarios—which translates to a high degree of long-COVID morbidity and COVID-19 mortality. Thus, accepting endemic SARS-CoV-2 is likely to result in large yearly US death tolls, with optimistic estimates exceeding 100,000 deaths annually. Precedented shifts in IFR could drive mortality to catastrophic levels, representing a plausible risk of the current public-health strategy and underlining the necessity of efforts to suppress SARS-CoV-2 transmission and evolution.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/covid2120121/s1>; Figure S1: Death tolls are increased under poor vaccine performance; Figure S2: Suppression of SARS-CoV-2 transmission mitigates reduced vaccine effectiveness against mortality; Table S1: Illustrative examples of the changes observed so far in the IFR and risk of hospitalization during the pandemic (March 2020–January 2021); Table S2: Estimation of the impact of shielding of older populations on apparent IFR using MA Covid tracker dataset (January 2021) as an example; Table S3: IFRs and relative transmissibilities of SARS-CoV-2 ancestral strain and VoCs. Reference [138] is cited in Supplementary Materials.

Author Contributions: Conceptualization, A.C., M.S., D.V.E. and A.N.; methodology, M.S., A.C., and A.N.; software, M.S.; validation, M.S., A.C. and S.S.; formal analysis, M.S., A.C. and S.S.; investigation, M.S., A.C. and S.S.; resources, M.S. and A.C.; data curation, M.S., A.C. and S.S.; writing—original draft preparation, A.N., M.S. and A.C.; writing—review and editing, M.S., A.N., S.S., D.V.E., L.F.W., N.S.H., M.S.R., D.J.-M., B.Z. and A.C.; visualization, M.S., S.S. and A.C.; supervision, L.F.W., N.S.H., M.S.R., B.Z. and A.C.; project administration, A.C.; funding acquisition, A.C. All authors have read and agreed to the published version of the manuscript.

Funding: A.N. acknowledges funding from the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE-1762114 and L.F.W. acknowledges funding from the National Institutes of Health, R35GM141821. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation or National Institutes of Health.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article and Supplementary Materials.

Acknowledgments: We acknowledge Dustin Doss for suggesting the article title.

Conflicts of Interest: M.S. and A.C. are employees of Fractal Therapeutics, Inc. Fractal Therapeutics has no business interest in the topic of the article.

References

1. Writer, A.P.H.S. Anthony Fauci Offers a Timeline for Ending COVID-19 Pandemic. *Harvard Gazette*, 10 December 2020.
2. Halperin, D.T.; Hearst, N.; Hodgins, S.; Bailey, R.C.; Klausner, J.D.; Jackson, H.; Wamai, R.G.; Ladapo, J.A.; Over, M.; Baral, S.; et al. Revisiting COVID-19 Policies: 10 Evidence-Based Recommendations for Where to Go from Here. *BMC Public Health* **2021**, *21*, 2084. [[CrossRef](#)]
3. Subbarao, K. The Success of SARS-CoV-2 Vaccines and Challenges Ahead. *Cell Host Microbe* **2021**, *29*, 1111–1123. [[CrossRef](#)] [[PubMed](#)]
4. Stieg, C. From Vaccines to Safe Socialization: Here's What to Expect in 2021, According to Experts. *CNBC*, 2 January 2021.
5. Picard, A. Opinion: How Will the Pandemic End? Not with a Moment of Triumph We'll All Remember, but with a Slow Whimper We'll Soon Forget. *The Globe and Mail*, 2 January 2020.
6. Makary, M. Opinion | We'll Have Herd Immunity by April. *Wall Street Journal*, 18 February 2021.
7. Aridi, S. What's the First Thing You Will Do When the Pandemic Ends? *The New York Times*, 2 January 2021.
8. Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection. *Nat. Med.* **2021**, *27*, 1205–1211. [[CrossRef](#)] [[PubMed](#)]
9. Lumley, S.F.; Wei, J.; O'Donnell, D.; Stoesser, N.E.; Matthews, P.C.; Howarth, A.; Hatch, S.B.; Marsden, B.D.; Cox, S.; James, T.; et al. Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. *Clin. Infect. Dis.* **2021**, *73*, e699–e709. [[CrossRef](#)]
10. Van Egeren, D.; Novokhodko, A.; Stoddard, M.; Tran, U.; Zetter, B.; Rogers, M.; Pentelute, B.L.; Carlson, J.M.; Hixon, M.; Joseph-McCarthy, D.; et al. Risk of Rapid Evolutionary Escape from Biomedical Interventions Targeting SARS-CoV-2 Spike Protein. *PLoS ONE* **2021**, *16*, e0250780. [[CrossRef](#)] [[PubMed](#)]
11. Hirabara, S.M.; Serdan, T.D.A.; Gorjao, R.; Masi, L.N.; Pithon-Curi, T.C.; Covas, D.T.; Curi, R.; Durigon, E.L. SARS-COV-2 Variants: Differences and Potential of Immune Evasion. *Front. Cell Infect. Microbiol.* **2021**, *11*, 781429. [[CrossRef](#)]
12. Singanayagam, A.; Hakki, S.; Dunning, J.; Madon, K.J.; Crone, M.A.; Koycheva, A.; Derqui-Fernandez, N.; Barnett, J.L.; Whitfield, M.G.; Varro, R.; et al. Community Transmission and Viral Load Kinetics of the SARS-CoV-2 Delta (B.1.617.2) Variant in Vaccinated and Unvaccinated Individuals in the UK: A Prospective, Longitudinal, Cohort Study. *Lancet Infect. Dis.* **2022**, *22*, 183–195. [[CrossRef](#)]

13. Eyre, D.W.; Taylor, D.; Purver, M.; Chapman, D.; Fowler, T.; Pouwels, K.; Walker, A.S.; Peto, T.E. The Impact of SARS-Cov-2 Vaccination on Alpha and Delta Variant Transmission. *medRxiv* **2021**. [[CrossRef](#)]
14. Levin, A.T.; Hanage, W.P.; Owusu-Boaitey, N.; Cochran, K.B.; Walsh, S.P.; Meyerowitz-Katz, G. Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-Analysis, and Public Policy Implications. *Eur. J. Epidemiol.* **2020**, *35*, 1123–1138. [[CrossRef](#)] [[PubMed](#)]
15. COVID-19 Response Reporting Mass.Gov. Available online: <https://www.mass.gov/info-details/covid-19-response-reporting> (accessed on 6 March 2022).
16. Brandal, L.T.; MacDonald, E.; Veneti, L.; Ravlo, T.; Lange, H.; Naseer, U.; Feruglio, S.; Bragstad, K.; Hungnes, O.; Ødeskaug, L.E.; et al. Outbreak Caused by the SARS-CoV-2 Omicron Variant in Norway, November to December 2021. *Eurosurveillance* **2021**, *26*, 2101147. [[CrossRef](#)]
17. Brown, C.M. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings—Barnstable County, Massachusetts, July 2021. *MMWR Morb. Mortal Wkly. Rep.* **2021**, *70*, 1059–1062. [[CrossRef](#)] [[PubMed](#)]
18. Buttler, M. Denmark Declares Covid No Longer Poses Threat to Society. *Bloomberg*, 26 January 2022.
19. WHO, Europe Entering “Plausible Endgame” to COVID Pandemic. *ABC News*, 3 February 2022.
20. Press Briefing by White House COVID-19 Response Team and Public Health Officials. 2022. Available online: <https://www.whitehouse.gov/briefing-room/press-briefings/2022/01/12/press-briefing-by-white-house-covid-19-response-team-and-public-health-officials-78/> (accessed on 6 March 2022).
21. Klaassen, F.; Chitwood, M.H.; Cohen, T.; Pitzer, V.E.; Russi, M.; Swartwood, N.A.; Salomon, J.A.; Menzies, N.A. Population Immunity to Pre-Omicron and Omicron SARS-CoV-2 Variants in US States and Counties through December 1, 2021. *medRxiv* **2022**. preprint. [[CrossRef](#)]
22. Lavine, J.S.; Bjornstad, O.N.; Antia, R. Immunological Characteristics Govern the Transition of COVID-19 to Endemicity. *Science* **2021**, *371*, 741–745. [[CrossRef](#)]
23. Rascoe, A. Viruses Evolve and Weaken over Time—What Does That Mean for the Coronavirus? *NPR*, 9 January 2022.
24. Ewald, P.W. Evolution of Virulence. *Infect. Dis. Clin. N. Am.* **2004**, *18*, 1–15. [[CrossRef](#)] [[PubMed](#)]
25. Coyne, K.P.; Jones, B.R.D.; Kipar, A.; Chantrey, J.; Porter, C.J.; Barber, P.J.; Dawson, S.; Gaskell, R.M.; Radford, A.D. Lethal Outbreak of Disease Associated with Feline Calicivirus Infection in Cats. *Vet. Rec.* **2006**, *158*, 544–550. [[CrossRef](#)]
26. Marshall, I.D.; Fenner, F. Studies in the Epidemiology of Infectious Myxomatosis of Rabbits. *J. Hyg.* **1958**, *56*, 288–302. [[CrossRef](#)]
27. Kerr, P.J.; Cattadori, I.M.; Liu, J.; Sim, D.G.; Dodds, J.W.; Brooks, J.W.; Kennett, M.J.; Holmes, E.C.; Read, A.F. Next Step in the Ongoing Arms Race between Myxoma Virus and Wild Rabbits in Australia Is a Novel Disease Phenotype. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 9397–9402. [[CrossRef](#)]
28. Best, S.M.; Kerr, P.J. Coevolution of Host and Virus: The Pathogenesis of Virulent and Attenuated Strains of Myxoma Virus in Resistant and Susceptible European Rabbits. *Virology* **2000**, *267*, 36–48. [[CrossRef](#)]
29. DeJesus, E.; Costa-Hurtado, M.; Smith, D.; Lee, D.-H.; Spackman, E.; Kapczynski, D.R.; Torchetti, M.K.; Killian, M.L.; Suarez, D.L.; Swayne, D.E.; et al. Changes in Adaptation of H5N2 Highly Pathogenic Avian Influenza H5 Clade 2.3.4.4 Viruses in Chickens and Mallards. *Virology* **2016**, *499*, 52–64. [[CrossRef](#)]
30. Spackman, E.; Pantin-Jackwood, M.J.; Kapczynski, D.R.; Swayne, D.E.; Suarez, D.L. H5N2 Highly Pathogenic Avian Influenza Viruses from the US 2014–2015 Outbreak Have an Unusually Long Pre-Clinical Period in Turkeys. *BMC Vet. Res.* **2016**, *12*, 260. [[CrossRef](#)]
31. Herbeck, J.T.; Müller, V.; Maust, B.S.; Ledergerber, B.; Torti, C.; Di Giambenedetto, S.; Gras, L.; Günthard, H.F.; Jacobson, L.P.; Mullins, J.I.; et al. Is the Virulence of HIV Changing? A Meta-Analysis of Trends in Prognostic Markers of HIV Disease Progression and Transmission. *AIDS* **2012**, *26*, 193–205. [[CrossRef](#)] [[PubMed](#)]
32. Fraser, C.; Hollingsworth, T.D.; Chapman, R.; de Wolf, F.; Hanage, W.P. Variation in HIV-1 Set-Point Viral Load: Epidemiological Analysis and an Evolutionary Hypothesis. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 17441–17446. [[CrossRef](#)] [[PubMed](#)]
33. Wymant, C.; Bezemer, D.; Blanquart, F.; Ferretti, L.; Gall, A.; Hall, M.; Golubchik, T.; Bakker, M.; Ong, S.H.; Zhao, L.; et al. A Highly Virulent Variant Of HIV-1 Circulating in the Netherlands. *Science* **2022**, *375*, 540–545. [[CrossRef](#)] [[PubMed](#)]
34. Department of Commerce Bureau of the Census, Mortality Statistics 1918. Available online: https://www.cdc.gov/nchs/data/vsushistorical/mortstatsh_1918.pdf (accessed on 6 March 2022).
35. Tumpey, T.M.; Basler, C.F.; Aguilar, P.V.; Zeng, H.; Solórzano, A.; Swayne, D.E.; Cox, N.J.; Katz, J.M.; Taubenberger, J.K.; Palese, P.; et al. Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus. *Science* **2005**, *310*, 77–80. [[CrossRef](#)] [[PubMed](#)]
36. Watanabe, T.; Kawaoka, Y. Pathogenesis of the 1918 Pandemic Influenza Virus. *PLoS Pathog.* **2011**, *7*, e1001218. [[CrossRef](#)]
37. Sofonea, M.T.; Aldakak, L.; Boullosa, L.F.V.V.; Alizon, S. Can Ebola Virus Evolve to Be Less Virulent in Humans? *J. Evol. Biol.* **2018**, *31*, 382–392. [[CrossRef](#)]
38. Haller, S.L.; Peng, C.; McFadden, G.; Rothenburg, S. Poxviruses and the Evolution of Host Range and Virulence. *Infect. Genet. Evol.* **2014**, *21*, 15–40. [[CrossRef](#)]
39. Dumbell, K.R.; Wells, D.G. The Pathogenicity of Variola Virus. A Comparison of the Growth of Standard Strains of Variola Major and Variola Minor Viruses in Cell Cultures from Human Embryos. *J. Hyg.* **1982**, *89*, 389–397. [[CrossRef](#)] [[PubMed](#)]
40. Huq, F.; Dumbell, K.R. Virulence of Variola Viruses for Suckling Mice. *Trans. R. Soc. Trop. Med. Hyg.* **2003**, *97*, 97–99. [[CrossRef](#)]

41. Fisman, D.N.; Tuite, A.R. Evaluation of the Relative Virulence of Novel SARS-CoV-2 Variants: A Retrospective Cohort Study in Ontario, Canada. *CMAJ* **2021**, *193*, E1619–E1625. [[CrossRef](#)]
42. Davies, N.G.; Jarvis, C.I.; Edmunds, W.J.; Jewell, N.P.; Diaz-Ordaz, K.; Keogh, R.H. Increased Mortality in Community-Tested Cases of SARS-CoV-2 Lineage, B.1.1.7. *Nature* **2021**, *593*, 270–274. [[CrossRef](#)]
43. Faria, N.R.; Mellan, T.A.; Whittaker, C.; Claro, I.M.; Candido, D.D.S.; Mishra, S.; Crispim, M.A.E.; Sales, F.C.S.; Hawryluk, I.; McCrone, J.T.; et al. Genomics and Epidemiology of the P.1 SARS-CoV-2 Lineage in Manaus, Brazil. *Science* **2021**, *372*, 815–821. [[CrossRef](#)]
44. Meyerowitz-Katz, G.; Merone, L. A Systematic Review and Meta-Analysis of Published Research Data on COVID-19 Infection Fatality Rates. *Int. J. Infect. Dis.* **2020**, *101*, 138–148. [[CrossRef](#)] [[PubMed](#)]
45. Davies, N.G.; Abbott, S.; Barnard, R.C.; Jarvis, C.I.; Kucharski, A.J.; Munday, J.D.; Pearson, C.A.; Russell, T.W.; Tully, D.C.; Washburne, A.D.; et al. Estimated Transmissibility and Impact of SARS-Cov-2 Lineage B. 1.1. 7 in England. *Science* **2021**, *372*, eabg3055. [[CrossRef](#)]
46. Abu-Raddad, L.J.; Chemaitelly, H.; Ayoub, H.H.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Tang, P.; Hasan, M.R.; Coyle, P.; AlMukdad, S.; et al. Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. *Clin. Infect. Dis.* **2021**, *75*, e1188–e1191. [[CrossRef](#)] [[PubMed](#)]
47. Pearson, C.A.B.; Russell, T.J.; Davies, N.; Kucharski, A.J.; CMMID COVID-19 working group; Edmunds, W.J.; Eggo, R.M. Estimates of Severity and Transmissibility of Novel SARS-CoV-2 Variant 501Y.V2 in South Africa. *CMMID Repository*, 1 November 2021. Available online: https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf (accessed on 6 March 2022).
48. Liu, Y.; Rocklöv, J. The Reproductive Number of the Delta Variant of SARS-CoV-2 Is Far Higher Compared to the Ancestral SARS-CoV-2 Virus. *J. Travel Med.* **2021**, *28*, taab124. [[CrossRef](#)] [[PubMed](#)]
49. Liu, Y.; Yu, Y.; Zhao, Y.; He, D. *Reduction in the Infection Fatality Rate of Omicron (B.1.1.529) Variant Compared to Previous Variants in South Africa*; Social Science Research Network: Rochester, NY, USA, 2022.
50. Lyngse, F.P.; Mortensen, L.H.; Denwood, M.J.; Christiansen, L.E.; Møller, C.H.; Skov, R.L.; Spiess, K.; Fomsgaard, A.; Lassaunière, M.M.; Rasmussen, M.; et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. *medRxiv* **2021**. [[CrossRef](#)]
51. O’Driscoll, M.; Ribeiro Dos Santos, G.; Wang, L.; Cummings, D.A.T.; Azman, A.S.; Paireau, J.; Fontanet, A.; Cauchemez, S.; Salje, H. Age-Specific Mortality and Immunity Patterns of SARS-CoV-2. *Nature* **2021**, *590*, 140–145. [[CrossRef](#)]
52. Wu, X.; Nethery, R.C.; Sabath, M.B.; Braun, D.; Dominici, F. Air Pollution and COVID-19 Mortality in the United States: Strengths And Limitations of An Ecological Regression Analysis. *Sci. Adv.* **2020**, *6*, eabd4049. [[CrossRef](#)] [[PubMed](#)]
53. Madhi, S.; Kwatra, G.; Myers, J.E.; Jassat, W.; Dhar, N.; Mukendi, C.K.; Nana, A.; Blumberg, L.; Welch, R.; Ngorima-Mabhena, N.; et al. South African population immunity and severe Covid-19 with omicron variant. *medRxiv* **2021**. [[CrossRef](#)]
54. CHEST 2021: Mechanical Ventilation Associated with Higher Mortality in COVID-19 Patients. Available online: <https://www.practiceupdate.com/content/chest-2021-mechanical-ventilation-associated-with-higher-mortality-in-covid-19-patients/126115> (accessed on 6 March 2022).
55. Yeates, E.O.; Nahmias, J.; Chinn, J.; Sullivan, B.; Stopenski, S.; Amin, A.N.; Nguyen, N.T. Improved Outcomes over Time for Adult COVID-19 Patients with Acute Respiratory Distress Syndrome or Acute Respiratory Failure. *PLoS ONE* **2021**, *16*, e0253767. [[CrossRef](#)] [[PubMed](#)]
56. Janke, A.T.; Mei, H.; Rothenberg, C.; Becher, R.D.; Lin, Z.; Venkatesh, A.K. Analysis of Hospital Resource Availability and COVID-19 Mortality Across the United States. *J. Hosp. Med.* **2021**, *16*, 211–214. [[CrossRef](#)]
57. Olivas-Martínez, A.; Cárdenas-Fragoso, J.L.; Jiménez, J.V.; Lozano-Cruz, O.A.; Ortiz-Brizuela, E.; Tovar-Méndez, V.H.; Medrano-Borromeo, C.; Martínez-Valenzuela, A.; Román-Montes, C.M.; Martínez-Guerra, B.; et al. In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. *PLoS ONE* **2021**, *16*, e0245772. [[CrossRef](#)] [[PubMed](#)]
58. SARS-CoV-2 Variants of Concern and Variants under Investigation in England. *UK Health Security Agency*, 31 December 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf (accessed on 6 March 2022).
59. REGEN-COV. Antibody Combination and Outcomes in Outpatients with Covid-19 | NEJM. Available online: <https://www.nejm.org/doi/full/10.1056/NEJMoa2108163> (accessed on 6 March 2022).
60. FDA Halts Use of Regeneron and Eli Lilly Antibody Drugs That Don’t Work against Covid Omicron. Available online: <https://www.cnbc.com/2022/01/24/fda-halts-use-of-antibody-drugs-that-dont-work-against-covid-omicron-.html> (accessed on 6 March 2022).
61. Bariola, J.R.; McCreary, E.K.; Wadas, R.J.; Kip, K.E.; Marroquin, O.C.; Minnier, T.; Koscumb, S.; Collins, K.; Schmidhofer, M.; Shovel, J.A.; et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Open Forum Infect. Dis.* **2021**, *8*, ofab254. [[CrossRef](#)] [[PubMed](#)]
62. He, X.; Lau, E.H.Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y.C.; Wong, J.Y.; Guan, Y.; Tan, X.; et al. Temporal Dynamics in Viral Shedding and Transmissibility of COVID-19. *Nat. Med.* **2020**, *26*, 672–675. [[CrossRef](#)]
63. Bai, J.; Shi, F.; Cao, J.; Wen, H.; Wang, F.; Mubarik, S.; Liu, X.; Yu, Y.; Ding, J.; Yu, C. The Epidemiological Characteristics of Deaths with COVID-19 in the Early Stage of Epidemic in Wuhan, China. *Glob. Health Res. Policy* **2020**, *5*, 54. [[CrossRef](#)]

64. Abu-Raddad, L.J.; Chemaitelly, H.; Ayoub, H.H.; Tang, P.; Coyle, P.; Hasan, M.R.; Yassine, H.M.; Benslimane, F.M.; Khatib, H.A.A.; Kanaani, Z.A.; et al. Effect of Vaccination and of Prior Infection on Infectiousness of Vaccine Breakthrough Infections and Reinfections. *medRxiv* **2021**. [CrossRef]
65. Levine-Tiefenbrun, M.; Yelin, I.; Alapi, H.; Katz, R.; Herzel, E.; Kuint, J.; Chodick, G.; Gazit, S.; Patalon, T.; Kishony, R. Viral Loads of Delta-Variant SARS-CoV-2 Breakthrough Infections after Vaccination and Booster with BNT162b2. *Nat. Med.* **2021**, *27*, 2108–2110. [CrossRef] [PubMed]
66. Levine-Tiefenbrun, M.; Yelin, I.; Alapi, H.; Herzel, E.; Kuint, J.; Chodick, G.; Gazit, S.; Patalon, T.; Kishony, R. Waning of SARS-CoV-2 Booster Viral-Load Reduction Effectiveness. *Nat. Commun.* **2022**, *13*, 1237. [CrossRef]
67. Kuhlmann, C.; Mayer, C.K.; Claassen, M.; Maponga, T.; Burgers, W.A.; Keeton, R.; Riou, C.; Sutherland, A.D.; Suliman, T.; Shaw, M.L.; et al. Breakthrough Infections with SARS-CoV-2 Omicron despite mRNA Vaccine Booster Dose. *Lancet* **2022**, *399*, 625–626. [CrossRef]
68. Stoddard, M.; Sarkar, S.; Yuan, L.; Nolan, R.P.; White, D.E.; White, L.F.; Hochberg, N.S.; Chakravarty, A. Beyond the New Normal: Assessing the Feasibility of Vaccine-Based Suppression of SARS-CoV-2. *PLoS ONE* **2021**, *16*, e0254734. [CrossRef] [PubMed]
69. Lauer, S.A.; Grantz, K.H.; Bi, Q.; Jones, F.K.; Zheng, Q.; Meredith, H.R.; Azman, A.S.; Reich, N.G.; Lessler, J. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann. Intern. Med.* **2020**, *172*, 577–582. [CrossRef]
70. Rocklöv, J.; Sjödin, H.; Wilder-Smith, A. COVID-19 Outbreak on the Diamond Princess Cruise Ship: Estimating the Epidemic Potential and Effectiveness of Public Health Countermeasures. *J. Travel Med.* **2020**, *27*, taaa030. [CrossRef]
71. Underlying Cause of Death 1999–2020. Available online: <https://wonder.cdc.gov/wonder/help/ucd.html> (accessed on 6 March 2022).
72. CDC Surveillance System: Estimated and Projected Population in the U.S. Available online: <https://nccd.cdc.gov/ckd/detail.aspx?Qnum=Q155> (accessed on 6 March 2022).
73. Population of the U.S. by Sex and Age 2021. Available online: <https://www.statista.com/statistics/241488/population-of-the-us-by-sex-and-age/> (accessed on 6 March 2022).
74. Buchan, S.A.; Chung, H.; Brown, K.A. Effectiveness of COVID-19 vaccines against omicron or delta symptomatic infection and severe outcomes. *medRxiv* **2022**. [CrossRef]
75. Klompas, M. Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination. *JAMA* **2021**, *326*, 2018–2020. [CrossRef]
76. Iyer, A.S.; Jones, F.K.; Nodoushani, A.; Kelly, M.; Becker, M.; Slater, D.; Mills, R.; Teng, E.; Kamruzzaman, M.; Garcia-Beltran, W.F.; et al. Dynamics and Significance of the Antibody Response to SARS-CoV-2 Infection. *medRxiv* **2020**. [CrossRef]
77. Sanche, S.; Lin, Y.T.; Xu, C.; Romero-Severson, E.; Hengartner, N.; Ke, R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg. Infect. Dis. J.* **2020**, *26*, 1470–1477. [CrossRef]
78. CDC. COVID Data Tracker. Available online: <https://covid.cdc.gov/covid-data-tracker> (accessed on 6 March 2022).
79. Coutinho, R.M.; Marquitti, F.M.D.; Ferreira, L.S.; Borges, M.E.; da Silva, R.L.P.; Canton, O.; Portella, T.P.; Poloni, S.; Franco, C.; Plucinski, M.M.; et al. Model-Based Estimation of Transmissibility and Reinfection of SARS-CoV-2 P.1 Variant. *Commun. Med.* **2021**, *1*, 1–8. [CrossRef]
80. GISAID—NextStrain. Available online: <https://www.gisaid.org/phylogenetics/global/nextstrain/> (accessed on 6 March 2022).
81. FastStats. Available online: <https://www.cdc.gov/nchs/fastats/heart-disease.htm> (accessed on 6 March 2022).
82. CDC Burden of Influenza. Available online: <https://www.cdc.gov/flu/about/burden/index.html> (accessed on 6 March 2022).
83. United States COVID—Coronavirus Statistics—Worldometer. Available online: <https://www.worldometers.info/coronavirus/country/us/> (accessed on 6 March 2022).
84. Irons, N.J.; Raftery, A.E. Estimating SARS-CoV-2 Infections from Deaths, Confirmed Cases, Tests, and Random Surveys. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2103272118. [CrossRef]
85. Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J. Substantial Undocumented Infection Facilitates the Rapid Dissemination of Novel Coronavirus (SARS-CoV-2). *Science* **2020**, *368*, 489–493. [CrossRef]
86. Rippinger, C.; Bicher, M.; Urach, C.; Brunmeir, D.; Weibrecht, N.; Zauner, G.; Sroczynski, G.; Jahn, B.; Mühlberger, N.; Siebert, U.; et al. Evaluation of Undetected Cases during the COVID-19 Epidemic in Austria. *BMC Infect. Dis.* **2021**, *21*, 70. [CrossRef] [PubMed]
87. CDC. Cases, Data, and Surveillance. Available online: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html> (accessed on 6 March 2022).
88. Daily Testing Trends in the US—Johns Hopkins. Available online: <https://coronavirus.jhu.edu/testing/individual-states> (accessed on 6 March 2022).
89. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. *FDA*, 14 September 2021. Available online: <https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests> (accessed on 6 March 2022).
90. Carod-Artal, F.J. Post-COVID-19 Syndrome: Epidemiology, Diagnostic Criteria and Pathogenic Mechanisms Involved. *Rev. Neurol.* **2021**, *72*, 384–396. [CrossRef] [PubMed]

91. Thomson, E.C.; Rosen, L.E.; Shepherd, J.G.; Spreafico, R.; da Silva Filipe, A.; Wojcechowskyj, J.A.; Davis, C.; Piccoli, L.; Pascall, D.J.; Dillen, J.; et al. Circulating SARS-CoV-2 Spike N439K Variants Maintain Fitness While Evading Antibody-Mediated Immunity. *Cell* **2021**, *184*, 1171–1187.e20. [[CrossRef](#)] [[PubMed](#)]
92. Makhoul, M.; Ayoub, H.H.; Chemaitelly, H.; Seedat, S.; Mumtaz, G.R.; Al-Omari, S.; Abu-Raddad, L.J. Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. *Vaccines* **2020**, *8*, E668. [[CrossRef](#)] [[PubMed](#)]
93. Iboi, E.A.; Ngonghala, C.N.; Gumel, A.B. Will an Imperfect Vaccine Curtail the COVID-19 Pandemic in the U.S.? *Infect. Dis. Model.* **2020**, *5*, 510–524. [[CrossRef](#)]
94. Escandón, K.; Rasmussen, A.L.; Bogoch, I.I.; Murray, E.J.; Escandón, K.; Popescu, S.V.; Kindrachuk, J. COVID-19 False Dichotomies and a Comprehensive Review of the Evidence Regarding Public Health, COVID-19 Symptomatology, SARS-CoV-2 Transmission, Mask Wearing, and Reinfection. *BMC Infect. Dis.* **2021**, *21*, 710. [[CrossRef](#)] [[PubMed](#)]
95. FastStats. Available online: <https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm> (accessed on 6 March 2022).
96. Woolf, S.H.; Masters, R.K.; Aron, L.Y. Effect of the Covid-19 Pandemic in 2020 on Life Expectancy across Populations in the USA and Other High Income Countries: Simulations of Provisional Mortality Data. *BMJ* **2021**, *373*, n1343. [[CrossRef](#)]
97. Mazzucco, S.; Campostrini, S. Life Expectancy Drop in 2020. Estimates Based on Human Mortality Database. *PLoS ONE* **2022**, *17*, e0262846. [[CrossRef](#)] [[PubMed](#)]
98. King, K.L.; Wilson, S.; Napolitano, J.M.; Sell, K.J.; Rennert, L.; Parkinson, C.L.; Dean, D. SARS-CoV-2 Variants of Concern Alpha and Delta Show Increased Viral Load in Saliva. *medRxiv* **2022**. [[CrossRef](#)]
99. Teyssou, E.; Delagrèverie, H.; Visseaux, B.; Lambert-Niclot, S.; Brichler, S.; Ferre, V.; Marot, S.; Jary, A.; Todesco, E.; Schnuriger, A.; et al. The Delta SARS-CoV-2 Variant Has a Higher Viral Load than the Beta and the Historical Variants in Nasopharyngeal Samples from Newly Diagnosed COVID-19 Patients. *J. Infect.* **2021**, *83*, e1–e3. [[CrossRef](#)]
100. Kidd, M.; Richter, A.; Best, A.; Cumley, N.; Mirza, J.; Percival, B.; Mayhew, M.; Megram, O.; Ashford, F.; White, T.; et al. S-Variant SARS-CoV-2 Lineage B.1.1.7 Is Associated with Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction. *J. Infect. Dis.* **2021**, *223*, 1666–1670. [[CrossRef](#)]
101. Spiesschaert, B.; McFadden, G.; Hermans, K.; Nauwynck, H.; Van de Walle, G.R. The Current Status and Future Directions of Myxoma Virus, a Master in Immune Evasion. *Vet. Res.* **2011**, *42*, 76. [[CrossRef](#)]
102. Bouayad, A. Innate Immune Evasion by SARS-CoV-2: Comparison with SARS-CoV. *Rev. Med. Virol.* **2020**, *30*, 1–9. [[CrossRef](#)] [[PubMed](#)]
103. Hayn, M.; Hirschenberger, M.; Koepke, L.; Nchioua, R.; Straub, J.H.; Klute, S.; Hunszinger, V.; Zech, F.; Prelli Bozzo, C.; Aftab, W.; et al. Systematic Functional Analysis of SARS-CoV-2 Proteins Uncovers Viral Innate Immune Antagonists and Remaining Vulnerabilities. *Cell Rep.* **2021**, *35*, 109126. [[CrossRef](#)] [[PubMed](#)]
104. Setaro, A.C.; Gaglia, M.M. All Hands on Deck: SARS-CoV-2 Proteins That Block Early Anti-Viral Interferon Responses. *Curr. Res. Virol. Sci.* **2021**, *2*, 100015. [[CrossRef](#)]
105. Xia, H.; Cao, Z.; Xie, X.; Zhang, X.; Chen, J.Y.-C.; Wang, H.; Menachery, V.D.; Rajsbaum, R.; Shi, P.-Y. Evasion of Type I Interferon by SARS-CoV-2. *Cell Rep.* **2020**, *33*, 108234. [[CrossRef](#)]
106. Chen, D.-Y.; Khan, N.; Close, B.J.; Goel, R.K.; Blum, B.; Tavares, A.H.; Kenney, D.; Conway, H.L.; Ewoldt, J.K.; Chitalia, V.C.; et al. SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway. *J. Virol.* **2021**, *95*, e0086221. [[CrossRef](#)]
107. Han, L.; Zhuang, M.-W.; Deng, J.; Zheng, Y.; Zhang, J.; Nan, M.-L.; Zhang, X.-J.; Gao, C.; Wang, P.-H. SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and CGAS-STING Signaling Pathways. *J. Med. Virol.* **2021**, *93*, 5376–5389. [[CrossRef](#)]
108. Shi, C.-S.; Qi, H.-Y.; Boullaran, C.; Huang, N.-N.; Abu-Asab, M.; Shelhamer, J.H.; Kehrl, J.H. SARS-Coronavirus Open Reading Frame-9b Suppresses Innate Immunity by Targeting Mitochondria and the MAVS/TRAF3/TRAF6 Signalosome. *J. Immunol.* **2014**, *193*, 3080–3089. [[CrossRef](#)]
109. Dominguez Andres, A.; Feng, Y.; Campos, A.R.; Yin, J.; Yang, C.-C.; James, B.; Murad, R.; Kim, H.; Deshpande, A.J.; Gordon, D.E.; et al. SARS-CoV-2 ORF9c Is a Membrane-Associated Protein That Suppresses Antiviral Responses in Cells. *bioRxiv* **2020**. [[CrossRef](#)]
110. Lu, F. SARS-CoV-2 ORF9c: A Mysterious Membrane-Anchored Protein That Regulates Immune Evasion? *Nat. Rev. Immunol.* **2020**, *20*, 648. [[CrossRef](#)] [[PubMed](#)]
111. Thoms, M.; Buschauer, R.; Ameismeier, M.; Koepke, L.; Denk, T.; Hirschenberger, M.; Kratzat, H.; Hayn, M.; Mackens-Kiani, T.; Cheng, J.; et al. Structural Basis for Translational Shutdown and Immune Evasion by the Nsp1 Protein of SARS-CoV-2. *Science* **2020**, *369*, 1249–1255. [[CrossRef](#)]
112. Kumar, A.; Ishida, R.; Strilets, T.; Cole, J.; Lopez-Orozco, J.; Fayad, N.; Felix-Lopez, A.; Elaish, M.; Evseev, D.; Magor, K.E.; et al. SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors. *J. Virol.* **2021**, *95*, e0026621. [[CrossRef](#)]
113. Li, J.-Y.; Liao, C.-H.; Wang, Q.; Tan, Y.-J.; Luo, R.; Qiu, Y.; Ge, X.-Y. The ORF6, ORF8 and Nucleocapsid Proteins of SARS-CoV-2 Inhibit Type I Interferon Signaling Pathway. *Virus Res.* **2020**, *286*, 198074. [[CrossRef](#)]
114. Kopecky-Bromberg, S.A.; Martínez-Sobrido, L.; Frieman, M.; Baric, R.A.; Palese, P. Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists. *J. Virol.* **2007**, *81*, 548–557. [[CrossRef](#)]

115. Li, M.; Liu, J.; Lu, R.; Zhang, Y.; Du, M.; Xing, M.; Wu, Z.; Kong, X.; Zhu, Y.; Zhou, X.; et al. Longitudinal Immune Profiling Reveals Dominant Epitopes Mediating Long-Term Humoral Immunity in COVID-19-Convalescent Individuals. *J. Allergy Clin. Immunol.* **2022**, *149*, 1225–1241. [CrossRef]
116. Premkumar, L.; Segovia-Chumbez, B.; Jadi, R.; Martinez, D.R.; Raut, R.; Markmann, A.; Cornaby, C.; Bartelt, L.; Weiss, S.; Park, Y.; et al. The Receptor Binding Domain of the Viral Spike Protein Is an Immunodominant and Highly Specific Target of Antibodies in SARS-CoV-2 Patients. *Sci. Immunol.* **2020**, *5*, eabc8413. [CrossRef]
117. Thorne, L.G.; Bouhaddou, M.; Reuschl, A.-K.; Zuliani-Alvarez, L.; Polacco, B.; Pelin, A.; Batra, J.; Whelan, M.V.X.; Hosmillo, M.; Fossati, A.; et al. Evolution of Enhanced Innate Immune Evasion by SARS-CoV-2. *Nature* **2022**, *602*, 487–495. [CrossRef]
118. Stoddard, M.; Yuan, L.; Sarkar, S.; Mangalaganesh, S.; Nolan, R.P.; Bottino, D.; Hather, G.; Hochberg, N.S.; White, L.F.; Chakravarty, A. Heterogeneity in vaccinal immunity to SARS-CoV-2 can be addressed by a personalized booster strategy. *medRxiv* 2022. [CrossRef]
119. Faes, C.; Abrams, S.; Van Beckhoven, D.; Meyfroidt, G.; Vlieghe, E.; Hens, N. Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients. *Int. J. Environ. Res. Public Health* **2020**, *17*, 7560. [CrossRef]
120. The Contribution of Nosocomial Infections to the First Wave. *Public Health England and the London School of Hygiene and Tropical Medicine*, 28 January 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961210/S1056_Contribution_of_nosocomial_infections_to_the_first_wave.pdf (accessed on 6 March 2022).
121. Donnelly, C.A.; Ghani, A.C.; Leung, G.M.; Hedley, A.J.; Fraser, C.; Riley, S.; Abu-Raddad, L.J.; Ho, L.-M.; Thach, T.-Q.; Chau, P.; et al. Epidemiological Determinants of Spread of Causal Agent of Severe Acute Respiratory Syndrome in Hong Kong. *Lancet* **2003**, *361*, 1761–1766. [CrossRef] [PubMed]
122. Breiman, R.F.; Evans, M.R.; Preiser, W.; Maguire, J.; Schnur, A.; Bekedam, H.; MacKenzie, J.S. Role of China in the Quest to Define and Control Severe Acute Respiratory Syndrome. *Emerg. Infect. Dis.* **2003**, *9*, 1037–1041. [CrossRef]
123. Al Hajjar, S.; Memish, Z.A.; McIntosh, K. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): A Perpetual Challenge. *Ann. Saudi Med.* **2013**, *33*, 427–436. [CrossRef] [PubMed]
124. Zhang, A.-R.; Shi, W.-Q.; Liu, K.; Li, X.-L.; Liu, M.-J.; Zhang, W.-H.; Zhao, G.-P.; Chen, J.-J.; Zhang, X.-A.; Miao, D.; et al. Epidemiology and Evolution of Middle East Respiratory Syndrome Coronavirus, 2012–2020. *Infect. Dis. Poverty* **2021**, *10*, 66. [CrossRef] [PubMed]
125. Ebrahim, S.H.; Maher, A.D.; Kanagasabai, U.; Alfaraj, S.H.; Alzahrani, N.A.; Alqahtani, S.A.; Assiri, A.M.; Memish, Z.A. MERS-CoV Confirmation Among 6,873 Suspected Persons and Relevant Epidemiologic and Clinical Features, Saudi Arabia—2014 to 2019. *EclinicalMedicine* **2021**, *41*, 101191. [CrossRef]
126. van der Ley, P.A.; Zariri, A.; van Riet, E.; Oosterhoff, D.; Kruiswijk, C.P. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. *Front Immunol.* **2021**, *12*, 781280. [CrossRef]
127. Bošnjak, B.; Odak, I.; Barros-Martins, J.; Sandrock, I.; Hammerschmidt, S.I.; Permanyer, M.; Patzer, G.E.; Georgiev, H.; Gutierrez Jauregui, R.; Tscherne, A.; et al. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. *Front Immunol.* **2021**, *12*, 772240. [CrossRef]
128. Afkhami, S.; D’Agostino, M.R.; Zhang, A.; Stacey, H.D.; Marzok, A.; Kang, A.; Singh, R.; Bavananthasivam, J.; Ye, G.; Luo, X.; et al. Respiratory Mucosal Delivery of Next-Generation COVID-19 Vaccine Provides Robust Protection against Both Ancestral and Variant Strains of SARS-CoV-2. *Cell* **2022**, *185*, 896–915.e19. [CrossRef]
129. Jiang, L.; Driedonks, T.A.P.; Jong, W.S.P.; Dhakal, S.; van den Berg van Saparoea, H.B.; Sitaras, I.; Zhou, R.; Caputo, C.; Littlefield, K.; Lowman, M.; et al. A Bacterial Extracellular Vesicle-Based Intranasal Vaccine against SARS-CoV-2 Protects against Disease and Elicits Neutralizing Antibodies to Wild-Type and Delta Variants. *bioRxiv* **2022**. [CrossRef]
130. Zhou, R.; Wang, P.; Wong, Y.-C.; Xu, H.; Lau, S.-Y.; Liu, L.; Mok, B.W.-Y.; Peng, Q.; Liu, N.; Woo, K.-F.; et al. Nasal Prevention of SARS-CoV-2 Infection by Intranasal Influenza-Based Boost Vaccination in Mouse Models. *EBioMedicine* **2022**, *75*, 103762. [CrossRef]
131. Cao, H.; Mai, J.; Zhou, Z.; Li, Z.; Duan, R.; Watt, J.; Chen, Z.; Bandara, R.A.; Li, M.; Ahn, S.K.; et al. Intranasal HD-Ad Vaccine Protects the Upper and Lower Respiratory Tracts of HACE2 Mice against SARS-CoV-2. *Cell Biosci.* **2021**, *11*, 202. [CrossRef]
132. Thapa, H.B.; Müller, A.M.; Camilli, A.; Schild, S. An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2. *Front. Microbiol.* **2021**, *12*, 752739. [CrossRef]
133. Liu, X.; Luongo, C.; Matsuoka, Y.; Park, H.-S.; Santos, C.; Yang, L.; Moore, I.N.; Afroz, S.; Johnson, R.F.; Lafont, B.A.P.; et al. A Single Intranasal Dose of a Live-Attenuated Parainfluenza Virus-Vectored SARS-CoV-2 Vaccine Is Protective in Hamsters. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2109744118. [CrossRef]
134. King, R.G.; Silva-Sanchez, A.; Peel, J.N.; Botta, D.; Dickson, A.M.; Pinto, A.K.; Meza-Perez, S.; Allie, S.R.; Schultz, M.D.; Liu, M.; et al. Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge. *Vaccines* **2021**, *9*, 881. [CrossRef]
135. Abaluck, J.; Kwong, L.H.; Styczynski, A.; Haque, A.; Kabir, M.A.; Bates-Jefferys, E.; Crawford, E.; Benjamin-Chung, J.; Raihan, S.; Rahman, S.; et al. Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh. *Science* **2022**, *375*, p.eabi9069. [CrossRef]
136. Nazarenko, Y. Air Filtration and SARS-CoV-2. *Epidemiol. Health* **2020**, *42*, e2020049. [CrossRef]

-
137. Cinaglia, P.; Cannataro, M. Forecasting COVID-19 Epidemic Trends by Combining a Neural Network with Rt Estimation. *Entropy* **2022**, *24*, 929. [[CrossRef](#)]
 138. Weinreich, D.M.; Sivapalasingam, S.; Norton, T.; Ali, S.; Gao, H.; Bhole, R.; Xiao, J.; Hooper, A.T.; Hamilton, J.D.; Musser, B.J.; et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. *N. Engl. J. Med.* **2021**, *385*, e81. [[CrossRef](#)]